DCGI Allows Bharat Biotech For Intra-Nasal Vaccine Phase-3 Trials

New Delhi: The Drug Controller General of India (DCGI) has given its approval to Bharat Biotech to conduct phase-3 trials for its COVID-19 intra-nasal vaccine (BBV154).

According to a report by PTI, the approval was granted on Friday and the trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as a booster dose schedule.

''BBV154 (nasal covid vaccine) has received approval for phase-3 clinical trials. The trials will evaluate BBV154 nasal vaccine for both the two-dose primary schedule and booster dose schedule,'' the news agency quoted a source as saying.

An intranasal vaccine would not only be simple to administer but also reduce the use of needles and syringes, among others.

According to Chairman of Bharat Biotech Krishna Ella, it would also impact the overall cost of a vaccination drive.

Notably, BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.

Also read: Grand-daughter of Former Karnataka CM Yediyurappa Found Hanging In Bengaluru

Also watch: